Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria

Basit Öğe Kaydı
dc.authorid0000-0002-0356-3744
dc.contributor.authorDumlu, Rıdvan
dc.contributor.authorYurttutan Uyar, Neval
dc.contributor.authorAyaş, Meltem
dc.contributor.authorAksoy, Nilay
dc.contributor.authorÖztürk, Nur
dc.contributor.authorSesin Kocagöz, Ayşe
dc.date.accessioned2023-01-10T08:14:29Z
dc.date.available2023-01-10T08:14:29Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Sağlık Bilimleri Enstitüsü, Klinik Eczacılık Ana Bilim Dalı
dc.description.abstractBackground/aim: Our study investigated the susceptibility rate of ceftazidime-avibactam and the risk factors associated with its resistance by analyzing gram-negative bacteria isolated from various patient samples. Materials and methods: Between March and November 2020, 1119 gram-negative bacteria strains were isolated from patient samples in Acıbadem Healthcare Group hospitals; ceftazidime-avibactam susceptibility results were evaluated using a 10/4µg (Oxoid, UK) disc and evaluated according to Eucast 2020 recommendations. Patient and isolate characteristics that could be risk factors were retrospectively investigated and statistically analyzed using SPSS 25.0. Results: Male patients made up 52% (n = 581) of the study’s total patient population, and they averaged 55.5 ± 24.9 years old. Of 1119 gram-negative strains culture and antibiogram, 1023 (91.4%) were sensitive to ceftazidime-avibactam. An increased risk of resistance was observed with female gender (OR = 2.29; CI 95% [1.45–3.61]; p < 0.05), Pseudomonas aeruginosa (OR = 1.67, CI 95% [1.03–2.7]; p < 0.05), the presence of multidrug-resistance (MDR) (OR = 4.07, CI 95% [2.47–6.7]; p < 0.05) pandrug-resistance (PDR) (OR = 12, (CI) 95% [9.9–14.7] ]; p < 0.05) and admission to intensive care unit (ICU) (OR = 1.89, CI 95% [1.22–2.93]; p < 0.05). Conclusion: The resistance rate of ceftazidime-avibactam was found to be 8.6%, and it was thought that resistant strains produced metallo-ß-lactamase (MBL) type carbapenemase. Risk factors were female gender, Pseudomonas aeruginosa, MDR, PDR, and admission to ICU. Therefore, studying the ceftazidime-avibactam susceptibility test together with gram-negative bacteria identification, especially in groups at risk for resistance, is one of the important factors that can positively affect the success of treatment.
dc.identifier.citationDumlu, R., Yurttutan Uyar, N., Ayaş, M., Aksoy, N., Öztürk, N. ve Sesin Kocagöz, A. (2022). Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria. Turkish Journal of Medical Sciences, 52(6), 1839-1844. https://dx.doi.org/10.55730/1300-0144.5530
dc.identifier.doi10.55730/1300-0144.5530
dc.identifier.endpage1844
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue6
dc.identifier.pmid36945980
dc.identifier.scopus2-s2.0-85144503666
dc.identifier.scopusqualityQ3
dc.identifier.startpage1839
dc.identifier.trdizinid1145646
dc.identifier.urihttps://dx.doi.org/10.55730/1300-0144.5530
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10275
dc.identifier.volume52
dc.identifier.wos000906716200012en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.institutionauthorÖztürk, Nur
dc.language.isoen
dc.publisherTurkiye Klinikleri
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectAntimicrobial Agents
dc.subjectDrug-Resistant
dc.subjectMultidrug-Resistant
dc.subjectCeftazidime-Avibactam Combination
dc.subjectGram-Negative Bacteria
dc.titleInvestigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Ozturkk-Nur-2022.pdf
Boyut:
97.59 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Sağlık Bilimleri Enstitüsü Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu